Deutsche Zeitschrift für Onkologie 2012; 44(1): 17-25
DOI: 10.1055/s-0031-1298687
© Karl F. Haug Verlag MVS Medizinverlage Stuttgart GmbH & Co. KG

Prognose beim Mammakarzinom

Martina Vetter
Eva Johanna Kantelhardt
Christoph Thomssen
Further Information

Publication History

Publication Date:
28 March 2012 (online)


Die Nutzung von Prognosefaktoren zur adjuvanten Therapieentscheidung ist Standard bei Patientinnen mit neu diagnostiziertem Mammakarzinom. In der folgenden Übersicht werden etablierte und innovative Biomarker vorgestellt. Biologische Grundlage, Testverfahren und Bewertung durch aktuelle evidenzbasierte Leitlinien werden kritisch diskutiert. Ziel der modernen Medizin ist die individuelle Therapie der Patientin unter Vermeidung von Unter- oder Übertherapie.


The use of prognostic factors to decide on adjuvant therapy in patients with newly diagnosed breast cancer is state of the art. This short review presents established and innovative biomarkers. Basic biologic mechanisms, nature of the test as well as rating within current clinical guidelines are discussed critically. The aim is tailored therapy for the individual patient avoiding over- and undertherapie.

  • Literatur

  • 1 Albain K, Barlow WE, Ravdin PM et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010; 11: 55-65
  • 2 Albain KS, Paik S, van’t Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009; Oct. 18 Suppl 3: 141-145
  • 3 Binder BR, Mihaly J, Prager GW. uPAR – uPA – PAI-1interactions and signaling: A vascular biologist’s view. Throm Haemost 2007; 97: 336-342
  • 4 Cardoso F, Piccart-Gebhart M, van’t Veer L, Rutgers E. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 2007; 1 (3): 246-51
  • 5 Cardoso F, van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26 (5): 729-35
  • 6 Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50
  • 7 Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S. Diseases of the breast. Philadelphia: Lippincott-Raven Publ; 1996: 461-485
  • 8 Cuzick J, Dowsett M, Pineda S, Wale C et al. Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison with the Genomic Health Recurrence Score in Early Breast Cancer. J Clin Oncol 2011; 29: 4273-4278
  • 9 Dowsett M, Nielsen TO, A’Hern R, Bartlett J et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656-1664
  • 10 Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379 (9814): 432-44
  • 11 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410
  • 12 Filipits M, Rudas M, Jakesz R, Dubsky P et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17 (18): 6012-20
  • 13 Gianni L, Dafni U, Gelber RD et al Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12 (3): 236-44
  • 14 Glas et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2002; 7: 728
  • 15 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22 (8): 1736-47
  • 16 Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-64
  • 17 Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002; 62: 4617-4622
  • 18 Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312
  • 19 Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2628-2634
  • 20 Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M. German N0 Study Group: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20
  • 21 Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel. BMC Cancer 2011; 11: 140
  • 22 Kreienberg R, Kopp I, Albert U, Bartsch HH et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. München: Zuckschwerdt; 2008
  • 23 Look MP, van Putten WL, Duffy MJ, Harbeck N et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28
  • 24 McGuire WL, Tandon AK, Alred DC, Chamness GC, Clark GM. Commentaries. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 1006-1015
  • 25 Nixon AJ, Neuberg D, Hayes DF et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1995; 12: 888-894
  • 26 Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826
  • 27 Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167
  • 28 Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52
  • 29 Rakha E et al. Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor–Positive Phenotype. J Clin Oncol 2007; 25: 4772-4778
  • 30 Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03–04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011; 47(18): 2742-9
  • 31 Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011; 11 (6): 617-34
  • 32 Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R Austrian Breast and Colorectal Cancer Study Group Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004; 240 (2): 306-12
  • 33 Sørlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2007; 360: 91-114
  • 34 Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning EysteinP, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74
  • 35 Sotiriou C, Pusztai L. Gene-expression signa­tures in breast cancer. N Engl J Med 2009; 360: 790-800
  • 36 Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98 (4): 262-72
  • 37 Sweep FC, Fritsche HA, Gion M et al. Considerations on development, validation, application and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. Int J Oncol 2003; 23: 1715-1726
  • 38 Thomssen C, Jänicke F, Harbeck N. Clinical relevance of prognostic factors in axillary node-negative breast cancer. Onkologie 2003; 26: 438-45
  • 39 Thomssen C, Vetter M, Schmidt M, Veyret C, Meisner C, von Minckwitz G, Martin P, Sweep F, Paepke D, Harbeck N on behalf of the NNBC-3 Study Group. ASCO recommended prognostic factors uPA and PAI-1 in node-negative breast cancer patients compared to clinico-pathological risk assessment in the NNBC 3-Europe trial. J Clin Oncol 2009; 27 (15): 544
  • 40 Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 2009; 10: 424
  • 41 van’t Veer LJ, Dai H, van de Vijver MJ. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536
  • 42 van de Vijver MJ, He YD, van’t Veer LJ. et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009
  • 43 Viale G, Giobbie-Hurder A, Regan MM, Coates AS Breast International Group Trial 1–98 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26 (34): 5569-75
  • 44 Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L Cancer and Leukemia Group B Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 2003; 21 (9): 1825-35
  • 45 Wo JY, Chen K, Neville BA et al Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 2011; 29: 2619-2627
  • 46 Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommenda­tions for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145
  • 47 Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11 (2): 174-183